These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22177062)

  • 1. A risk-based statistical investigation of the quantification of polymorphic purity of a pharmaceutical candidate by solid-state 19F NMR.
    Barry SJ; Pham TN; Borman PJ; Edwards AJ; Watson SA
    Anal Chim Acta; 2012 Jan; 712():30-6. PubMed ID: 22177062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state (13)C CPMAS NMR spectroscopy.
    Virtanen T; Maunu SL
    Int J Pharm; 2010 Jul; 394(1-2):18-25. PubMed ID: 20416365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of solid polymer dispersions of active pharmaceutical ingredients by 19F MAS NMR and factor analysis.
    Urbanova M; Brus J; Sedenkova I; Policianova O; Kobera L
    Spectrochim Acta A Mol Biomol Spectrosc; 2013 Jan; 100():59-66. PubMed ID: 22421443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of compaction-induced crystallinity reduction of a pharmaceutical solid using 19F solid-state NMR and powder X-ray diffraction.
    Liu J; Nagapudi K; Kiang YH; Martinez E; Jona J
    Drug Dev Ind Pharm; 2009 Aug; 35(8):969-75. PubMed ID: 19360510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of quantitative 19F and 1H NMR for reaction monitoring and in situ yield determinations for an early stage pharmaceutical candidate.
    Do NM; Olivier MA; Salisbury JJ; Wager CB
    Anal Chem; 2011 Nov; 83(22):8766-71. PubMed ID: 21972901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved solid-state NMR quantifications of active principles in pharmaceutical formulations.
    Sanchez S; Ziarelli F; Viel S; Delaurent C; Caldarelli S
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):683-7. PubMed ID: 18479881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding API-polymer proximities in amorphous stabilized composite drug products using fluorine-carbon 2D HETCOR solid-state NMR.
    Abraham A; Crull G
    Mol Pharm; 2014 Oct; 11(10):3754-9. PubMed ID: 25152063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple assessment of homogeneity in pharmaceutical mixing processes using a near-infrared reflectance probe and control charts.
    Skibsted ET; Boelens HF; Westerhuis JA; Witte DT; Smilde AK
    J Pharm Biomed Anal; 2006 Apr; 41(1):26-35. PubMed ID: 16289623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations.
    Brus J; Urbanova M; Sedenkova I; Brusova H
    Int J Pharm; 2011 May; 409(1-2):62-74. PubMed ID: 21356299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Solid-state NMR spectroscopy and its pharmaceutical use].
    Marosi A; Szalay Z; Demeter A
    Acta Pharm Hung; 2010; 80(1):18-45. PubMed ID: 20443364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raman spectroscopy for the in-line polymer-drug quantification and solid state characterization during a pharmaceutical hot-melt extrusion process.
    Saerens L; Dierickx L; Lenain B; Vervaet C; Remon JP; De Beer T
    Eur J Pharm Biopharm; 2011 Jan; 77(1):158-63. PubMed ID: 20933084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing anhydrous and hydrous forms of an active pharmaceutical ingredient in a tablet formulation using solid-state NMR spectroscopy.
    Griffin JM; Martin DR; Brown SP
    Angew Chem Int Ed Engl; 2007; 46(42):8036-8. PubMed ID: 17847137
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of low-level PTFE contamination: An application of solid-state NMR to structure elucidation in the pharmaceutical industry.
    Pham TN; Day CJ; Edwards AJ; Wood HR; Lynch IR; Watson SA; Bretonnet AS; Vogt FG
    J Pharm Biomed Anal; 2011 Jan; 54(2):401-5. PubMed ID: 20880648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.
    Gavin PF; Olsen BA; Wirth DD; Lorenz KT
    J Pharm Biomed Anal; 2006 Jun; 41(4):1251-9. PubMed ID: 16621411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
    Cooper VB; Pearce GE; Petts CR
    J Pharm Pharmacol; 2003 Sep; 55(9):1323-9. PubMed ID: 14604477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of NIR spectroscopy to monitoring and analyzing the solid state during industrial crystallization processes.
    Févotte G; Calas J; Puel F; Hoff C
    Int J Pharm; 2004 Apr; 273(1-2):159-69. PubMed ID: 15010140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection, identification and quantification of a new de-fluorinated impurity in casopitant mesylate drug substance during late phase development: an analytical challenge involving a multidisciplinary approach.
    Turco L; Provera S; Curcuruto O; Bernabè E; Nicoletti A; Martini L; Castoldi D; Cimarosti Z; Papini D; Marchioro C; Dams R
    J Pharm Biomed Anal; 2011 Jan; 54(1):67-73. PubMed ID: 20813481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, validation and transfer of a near infrared method to determine in-line the end point of a fluidised drying process for commercial production batches of an approved oral solid dose pharmaceutical product.
    Peinado A; Hammond J; Scott A
    J Pharm Biomed Anal; 2011 Jan; 54(1):13-20. PubMed ID: 20801599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 19F solid-state NMR spectroscopic investigation of crystalline and amorphous forms of a selective muscarinic M3 receptor antagonist, in both bulk and pharmaceutical dosage form samples.
    Wenslow RM
    Drug Dev Ind Pharm; 2002 May; 28(5):555-61. PubMed ID: 12098844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.